Sales value of leading drugs Japan FY 2019

In the fiscal year 2019, "Keytruda" was the leading medicament in Japan, reaching a sales value of approximately 135.8 billion Japanese yen. Keytruda is an immunotherapy agent and is mainly used to treat malignant melanoma in Japan.

Annual sales value of leading medicines in Japan in fiscal year 2019

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until March 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

May 2020

Region

Japan

Survey time period

fiscal year 2019; the Japanese fiscal year starts April 1 of the stated year and ends March 31 of the following year

Supplementary notes

Figures have been rounded.
1 Japanese yen equals 0.0095 U.S. dollars or 0.0080 euros as of August 2020.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Pharmaceutical products: Crestor (rosuvastatin) and Nexium (esomeprazole)"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.